PubMed

Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.

Tunis SL, Willis WD, Foos V.

Curr Med Res Opin. 2009 Nov 18. [Epub ahead of print]PMID: 19919377 [PubMed - as supplied by publisher]Related articles

Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US.

Tunis SL, Minshall ME.

Curr Med Res Opin. 2009 Nov 18. [Epub ahead of print]PMID: 19919376 [PubMed - as supplied by publisher]Related articles

A Cost-Effectiveness Analysis to Illustrate the Impact of Cost Definitions on Results, Interpretations and Comparability of Pharmacoeconomic Studies in the US.

Tunis SL.

Pharmacoeconomics. 2009;27(9):735-44. doi: 10.2165/10899600-000000000-00000.PMID: 19757867 [PubMed - in process]Related articles

A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US *

Charles MS, Minshall ME, Pandya BJ, Baran RW, Tunis SL.

Curr Med Res Opin. 2009 May 6. [Epub ahead of print]PMID: 19419339 [PubMed - as supplied by publisher]Related articles

Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada.

St Charles ME, Sadri H, Minshall ME, Tunis SL.

Clin Ther. 2009 Mar;31(3):657-67.PMID: 19393856 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.

Tunis SL, Minshall ME, Conner C, McCormick JI, Kapor J, Yale JF, Groleau D.

Curr Med Res Opin. 2009 May;25(5):1273-84.PMID: 19366302 [PubMed - indexed for MEDLINE]Related articles

Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research.

Pelletier EM, Smith PJ, Boye KS, Misurski DA, Tunis SL, Minshall ME.

Appl Health Econ Health Policy. 2008;6(2-3):103-12. doi: 10.2165/00148365-200806020-00003.PMID: 19231904 [PubMed - indexed for MEDLINE]Related articles

Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US.

Tunis SL, Minshall ME, Charles MS, Pandya BJ, Baran RW.

Curr Med Res Opin. 2008 Sep 29. [Epub ahead of print]PMID: 18826750 [PubMed - as supplied by publisher]Related articles

The impact of clinical trial design on cost-effectiveness analyses: illustration from a published study of the one-touch ultrasmart blood glucose meter for insulin-using diabetes patients.

Tunis SL, Minshall ME.

Diabetes Technol Ther. 2008 Jun;10(3):227-31.PMID: 18473698 [PubMed - indexed for MEDLINE]Related articles

Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the united states.

Tunis SL, Minshall ME.

Am J Manag Care. 2008 Mar;14(3):131-40.PMID: 18333705 [PubMed - indexed for MEDLINE]Related articlesFree article

An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia.

Tunis SL, Faries DE, Stensland MD, Hay DP, Kinon BJ.

Curr Med Res Opin. 2007 Jan;23(1):97-104.PMID: 17257471 [PubMed - indexed for MEDLINE]Related articles

Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use.

Smelson DA, Tunis SL, Nyhuis AW, Faries DE, Kinon BJ, Ascher-Svanum H.

J Clin Psychopharmacol. 2006 Dec;26(6):666-7. No abstract available. PMID: 17110828 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.

Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R.

Value Health. 2006 Mar-Apr;9(2):77-89.PMID: 16626411 [PubMed - indexed for MEDLINE]Related articles

Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial.

Zhu B, Tunis SL, Zhao Z, Baker RW, Lage MJ, Shi L, Tohen M.

Curr Med Res Opin. 2005 Apr;21(4):555-64.PMID: 15899104 [PubMed - indexed for MEDLINE]Related articles

Cognitive and clinical predictors of success in vocational rehabilitation in schizophrenia.

Evans JD, Bond GR, Meyer PS, Kim HW, Lysaker PH, Gibson PJ, Tunis S.

Schizophr Res. 2004 Oct 1;70(2-3):331-42.PMID: 15329308 [PubMed - indexed for MEDLINE]Related articles

Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database.

Zhao Z, Namjoshi M, Barber BL, Loosbrock DL, Tunis SL, Zhu B, Breier A.

CNS Drugs. 2004;18(3):157-64.PMID: 14871159 [PubMed - indexed for MEDLINE]Related articles

Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs.

Tunis SL, Ascher-Svanum H, Stensland M, Kinon BJ.

Pharmacoeconomics. 2004;22(1):1-8. Review.PMID: 14720078 [PubMed - indexed for MEDLINE]Related articles

Response to vocational rehabilitation during treatment with first- or second-generation antipsychotics.

Bond GR, Kim HW, Meyer PS, Gibson PJ, Tunis S, Evans JD, Lysaker P, McCoy ML, Dincin J, Xie H.

Psychiatr Serv. 2004 Jan;55(1):59-66.PMID: 14699202 [PubMed - indexed for MEDLINE]Related articlesFree article

Characterizing behavioral and psychological symptoms of dementia (BPSD) among geropsychiatric inpatients.

Tunis SL, Edell WS, Adams BE, Kennedy JS.

J Am Med Dir Assoc. 2002 May-Jun;3(3):146-51.PMID: 12807658 [PubMed]Related articles

Assessing antipsychotic effectiveness in dementia with the factor structure of the Psychogeriatric Dependency Rating Scale (PGDRS).

Adams BE, Tunis SL, Edell WS.

J Am Med Dir Assoc. 2003 Mar-Apr;4(2):61-6.PMID: 12807576 [PubMed - indexed for MEDLINE]Related articles